University of Birmingham

Chromatwist they provide shifted organic fluorescent dyes which, when irradiated with UV light, become visible blue excitation sources. Their patented innovative molecular technology platform coupled to their modular and scalable chemistry allows the development of their fluorophores to further push the boundaries of applications in the healthcare sector through their use in bio-sensing (e.g. flow cytometry) and bio-imaging (e.g. multiphoton microscopy).

Linear Diagnostics Limited (LDL) is a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. The technology provides significant advantages over the current state of the art allowing a more rapid detection of multiple targets using a single simple reagent

Tyseley Energy Park develops an Energy Innovation Zone (EIZ) to help Tyseley and Birmingham overcome the severe energy business and social challenges it currently faces. The TEP EIZ reduces emissions and stimulates growth and will integrate low carbon technologies and infrastructure needed to support new approaches to clean energy.

Smart Antenna Technologies (SAT) is a spinout company from the University of Birmingham. The team have designed, developed and patented a pioneering smart antenna technology. The market for this highly scalable technology is the global cellular handset market. SAT's remarkable innovation has led to the creation of a significant number of patent applications, both filed and in process. Today, handset manufacturers are seeking an effective antenna solution suitable for implementing the next generation of cellular handset technologies, known as Long Term Evolution (4G LTE). Currently, they are unable to achieve physically the desired antenna performance in a size that fits a cellular handset package at an acceptable volume cost. Current implementations from the leading handset manufacturers employ typically six antennas. The highly compact SAT technology replaces all existing antennas—DVB-H, Bluetooth, Wi-Fi, GSM, GPS, 3G multi-bands and 3.9/4G LTE—with just one. This single SAT device provides significantly lower costs, is smaller in size and offers much needed performance gains over existing designs and technology.

Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease in the very early stages. Alzheimer's Disease affects over 26 million people world-wide and is a growing condition as people live longer. There is currently no cure for Alzheimer's Disease, but there are large international initiatives underway to find treatments with many drugs in clinical development. Cytox are commercially launching their tests in conjunction with Affymetrix (part of Thermo Fisher Scientific) to support Pharmaceutical and Biotechnology companies developing novel therapeutics.